🇺🇸 FDA
Patent

US 9707220

Scopolamine for the treatment of depression and anxiety

granted A61KA61K31/46A61K45/06

Quick answer

US patent 9707220 (Scopolamine for the treatment of depression and anxiety) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/46, A61K45/06, A61K9/0073, A61P